A vaccine that operates on the same principle as the jab for diphtheria and tetanus could be used to stamp out cases of the virulent hospital superbug Clostridium difficile, researchers say.

Scientists will start recruiting patients next year for clinical trials of the vaccine, which has the potential to prevent thousands of deaths in British hospitals each year.

The vaccine, given to healthy patients last year to check its safety, works by using a small quantity of formaldehyde to neutralise toxins emitted by the bacteria. In laboratory trials and tests on at least three patients with chronic C. difficile infections, it rendered these toxins harmless, helping the immune system to fight off illness naturally.

A jab against C. difficilecould be provided to at-risk groups within eight years, the researchers suggest.

C. difficile is the most common form of hospital-acquired infection and diarrhoea in the Western world. It contributed to the deaths of nearly 4,000 people last year.

Cases of the superbug, which is harder to control than MRSA, increased by 8 per cent last year compared with 2005.

Acambis, the company developing the vaccine, said that it was negotiating with the Department of Health and the Health Protection Agency on whether British patients could take part in the next stage of the trials.

The company, based in Cambridge, East Anglia, and Cambridge, Massachusetts, said that it had identified a number of vaccine formulations and planned to begin the second phase of trials towards the end of next year.

The bacterium occurs naturally in the intestines of 3 per cent of healthy adults and two thirds of infants, where it rarely causes problems. However, it can cause illness – from mild to severe diarrhoea, or in some cases severe inflammation of the bowel – when its growth is unchecked.

Treatment with antibiotics can disturb the balance of “normal” bacteria in the gut, allowing C. difficile to thrive.

Michael Watson, the executive vice-president for research and development at Acambis, said: “Formaldehyde may be best known as the pickling ingredient for Damien Hirst’s shark, but it’s also a key ingredient in vaccines against diphtheria, tetanus and whooping cough.

“In a typical C. difficile infection the toxins break apart and irritate the lining of the bowel. Our vaccine is designed to prevent this and render the toxins harmless, so they can be destroyed by the immune system.”

Most people can recover from an infection naturally but patients whose immune reaction is weakened by age or illness have trouble fighting off the bug. Infections can be treated with antibiotics but an estimated 20-30 per cent of patients suffer a relapse.

The vaccine could provide a longer-term solution to the problem, and counter the emergence of drug-resist-ant strains, Dr Watson said. “We estimate that between 2010 and 2015, patients could start seeing the benefits,” he added. The NHS is also using technology invented to protect Britain against biological weapons to fight superbugs. Air disinfection units, which kill up to 98.5 per cent of germs in the air, including drug-resistant strains of C. difficile, E. coli and MRSA, have been approved for use in hospitals after tests at Porton Down, the Government’s bio-warfare research centre in Wiltshire.

Maidstone and Tunbridge Wells hospitals trust in Kent, where at least 90 patients died as a result of C. difficile infections, will be the first to use the technology.

Explore Health

• Expert Advice

• Health Features

• Mental Health

• Alternative Medicine

• Child Health